drugset / Trial / NCT00978055

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

NCT00978055

Phase 1 Completed 31 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-label

Summary

The objective of this study was to investigate the bioequivalence of Mylan's liothyronine sodium 50 mcg tablets to King's Cytomel® 50 mcg tablets following a single, oral 100 mcg (2 x 50 mcg) dose administration under fasting conditions.

Timeline

Start
2007-10
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liothyronine Small molecule 100 ug Oral

Indications

No indication recorded.